DDS-06E:
SN-38

Our Product

Intravenous administration of oncology drugs often mandates dosing regimens that affect tolerability. We are developing an oral formulation of SN38, the active metabolite in the widely prescribed intravenous colon cancer drug irinotecan. In animal colon tumour xenograft studies, our oral formulation, which utilizes our micellar PNDS technology, showed equal efficacy to irinotecan administered intravenously.

An orally administered formulation of this product could provide significantly improved efficacy, safety and bespoke dosing flexibility.

Market Opportunity

SN-38 addresses a potential market opportunity of US$3 billion globally.

Status

Feasibility and formulation have been completed.